IN additio n to its w ell-e s tablis h ed e ffe ct o n T cells, cyclos p orin
Introduction
Cyc losporin A (CsA) is an immunomodulator y substanc e use d in the pre ve ntio n of trans plant re je ction and in the tre atme nt of autoimmune dis ease. 1 Classically, CsA has be en re porte d to ex e rt its immunomodulatory ac tion through its effect on T lymphocyte s, mainly helpe r T lymphoc yte s, by inhibiting c alcine urin depe nde nt inte rleukin-2 synthesis . 2, 3 Rece ntly, how e ver, it has bee n suggeste d that the inhibition of T lymphocyte ac tivation by CsA doe s not appropriate ly ac count for all the e ffec ts observe d follow ing in vivo adminis tratio n of the drug. 4 Ac cording ly, despite w ide spre ad use of the drug, the sp ecific me chanis m of ac tion of CsA re mains to be fully elucidate d. 5 It is also possible that its e ffec ts c ould be due in part to the ac tion of CsA on othe r cells. 6 In this se nse , it should be note d that CsA binds spe cific ally, re versibly and in a time -and te mperature -depende nt fashion to all human leucocyte s. How e ve r, granulocyte s and c ells of the mononuclear phagoc yte syste m (MPS) some time s bind more CsA than lymphocyte s, probably bec ause the drug is rapidly inte rnaliz ed. 2, 7 Ce lls of the MPS offe r an attrac tive possibility to study the effects of this drug because the y partic ipate in a crucial manne r in antige n pre se ntatio n and, in many c ase s, are the final effe ctors of the immune syste m. Many re fe re nce s in the lite rature re port the capacity of CsA to alte r the ac tivitie s of MPS ce lls. In gene ral, the capacitie s, func tions and ac tions of macrophage s re late d to non-spe cific de fe nse such as che motax is , phagocytosis , e nzyme re le as e and re spirator y burst, can be said to be more re sistant to CsA. 8, 9 By c ontras t, those re late d to immunore gulation or acc essory func tions , such as monokine production, the ex pre ssion of his toc ompatibility antigens and antige n pre sentation, are more susc eptible to the ac tion of CsA. 8, 9 Mac rophages synthe size and secre te IL-1b , TNF-a , IL-6 and IL-8. 10 These monokine s are know n mediators of the inflammator y re sponse 10 and are the re fore also know n as inflammatory cytokine s. It has be en re porte d that CsA inhibits the produc tion of IL-1b , TNF-a and IL-6 in diffe re nt c ells of the MPS. 11, 12 How e ver, the me chanism through w hich this oc curs is not w ell know n. 13 In the light of the fore going, the aim of the pre se nt study w as to e valuate and de te rmine the me chanism of ac tion of CsA on the produc tion of inte rleukin-6 by macrophage s. To do so, the human diffe re ntiate d U937 monoc yte line w as employed.
Methods

Cell line
U937 c ells w ere kindly supplie d by Dr J. Olmos of the Hospital Unive rs itario Marqués de Valde cilla, Santande r (Spain). The cell line w as ke pt at 37°C in a humidifie d atmosphere w ith 5% CO 2 in culture w ith complete medium c ontaining RPMI 1640 (Sigma®), 100 U/mL of p enic illin (Sigma®), 100 U/mL of stre ptomyc ine (Sigma®), 2 mM L-glutamine (Sigma®) and 10% fetal c alf se rum (FCS) (Gibc o®) in ste rile c ulture flasks (Nunclon®) at a conc entratio n betw e en 0.75 3 10 5 and 5 3 10 5 ce lls/mL. Ce ll viability w as gre ate r than 90% and the duplic atio n time w as be tw een 24 and 48 hours. Ce lls w e re re gularly scre ene d for lipopolysac charide (LPS), bac te ria, mycoplasma and fungal c ontamination and found to be ne gative . Ce lls w e re diffe rentiate d by c ulture ove r 4 days in complete me dium containing 1.3% dime thylsulfox ide (DMSO).
Cell cultures
5 3 10 5 ce lls togethe r w ith diffe re nt stimuli and/or CsA at the follow ing conc entratio n w ere adde d to each w ell of the culture dishes (Costar®) w ith comple te me dium: Lipopolysaccharide from E. co li (Sigma®) at 100 m g/mL and 10 m g/mL; phorbol-12-myristate -13-ace tate (PMA) (Sigma®) at 10 -4 M and 10 -5 M; human gamma-inte rfe ron (Sigma®) at 1000 U/mL and 100 U/mL and CsA (Sandoz®) at thre e non-tox ic c onc entratio ns in vivo : 200, 20 and 2 ng/mL.
Ce lls w e re kept at 37°C in a humifie d atmosphere w ith 5% CO 2 for 18 hours, afte r w hich the supernatants w e re c entrifuge d at 500 g for 10 min to se dime nt c ells in suspens ion and the n store d at -70°C until late r de te rmination.
Afte r the supernatant had bee n re move d, 400 m L of a 0.25 M sucrose -0.02 EDTA solution w as adde d to each w e ll. Afte r the bottom of each w ell had bee n sc rape d vigorous ly, the conte nt w as as pirate d and adde d to the pre vious ce ll pellet, thus re covering all the ce lls. The cells w ere the n subjec te d to heat disinte gration by re p eate d fre ezing -thaw ing (6 c ycle s of 10 min fre ezing and 15 min thaw ing) and w e re store d at -70°C until dete rmination .
To study the inhibitio n of early prote in synthe sis, cyclohex imide (Sigma®) at a concentration of 1 m g/mL w as adde d during the first 3 hours of cell culture .
Cytokine determination
The inflammatory cytokine IL-6 w as dete rmine d by dire ct double-sandw ich enzyme-linke d immunosorbent assay (ELISA) of antib odie s in the supe rnatants and c ell lysate s. BIOTRAK® (Ame rsham, UK) c ommercial kit spec ific for human IL-6 w as use d; this show e d no c ros s-re activity w ith othe r cytokine s. It had a coeffic ie nt of variation less than 10%, and a sens itivity limit of 0.35 pg/mL. All sample s w e re measure d in duplic ate . Re sults w ere ex pre ssed in pic ograms/10 6 ce lls. It should be note d that in ELISA assays none of the compone nts of the c ulture medium (RPMI 1640, antib iotic s, glutamine or fe tal c alf se rum) show e d immunore ac tivity w ith the c ytokine studie d.
IL-6 mRNA expression
Trans cription of the IL-6 ge ne w as studie d by Northern blot. Diffe re ntiate d U937 c ytoplasmic RNA w as isolate d by 150 mM NaCI, 1 mM MgCI2, 10 mM Tris-HCI pH 7.4, 0.5% Nonide t P40 and 250-1000 U/mL RNAs ing (Promega®) lysis, follow ed by tw o succ essive ultrac e ntrifug atio ns w ith Tris-buffe re d phe nol and 10% SDS and phenol, re sp ective ly. RNA w as pre c ipitate d ove rnight w ith cold ethanol and 3M sodium ac etate pH 7.2, and re dissolved in Tris-EDTA pH 7 buffe r. RNA w as quantifie d by dete rmining optic al density at a w ave length of 260 nm. The quality of the RNA w as che cke d by the demons tration of tw o bands corre sponding to ribosomal RNA (18s and 28s) and the absenc e of de gradation of the RNA by staining w ith ethidium bromide in the ele ctrophore sis of a 1% agarose minige l loade d w ith 1.5 m g of RNA.
RNA w as denature d by inc ubatio n for 1 h at 50°C in a solution of 1 M glyox al, 50% DMSO and 10 mM NaH 2 PO 4 . Follow ing this , 5 m g of RNA w e re mix e d w ith elec trophore sis sample buffer (50% glyc erol, 49.6% 10 mM NaH 2 PO 4 p H 7.0, 0.4% bromophe nol blue ). Afte r loading sample s, e le ctrop hore sis (35V) w as c arrie d out in 1% agarose -10 mM NaH 2 PO 4 pH 7 gels using 10 mM NaH 2 PO 4 pH 7 buffe r. Follow ing ele ctrophore sis, the RNA w as trans ferre d ove rnight by c apillarity from the ge l to a nitro cellulose membrane using 203 SSC. This membrane w as drie d w ith Whatman pape r and the RNA w as c ros s-linke d to the me mbrane by ex posure to UV light. Then, the me mbrane w as pre hybridize d for 2 h at 65°C in a solution containing 6.4% dex tran, 33 SSC, 13 Denhart's, 0.1% SDS and 250 m g/mL he at-de nature d salmon spe rm DNA. IL-6 cDNA and G3PDH cDNA probes comme rc ialize d by the Ame ric an Type Culture Colle ction (ATCC) w ere labelled w ith 32 P using the c ommercial 'Re ady To Go' kit (Pharmac ia Biote ch®) follow ing the protoc ol indic ate d by the manufac ture r. Hybridizatio n (18 h, 65°C) w as carrie d out using the same pre hybridiz atio n solution containing he at-de nature d 32 P-labe lle d probes. Follow ing succ essive w ashings in 0.1 SDS-0, 1 SSC at room te mperature and 65°C, re spe ctive ly, me mbrane s w ere blotte d dry and use d for autoradio graphy w ith XR film (Cronex 105, Dupont®) at -70°C ove r 6 days . Hybridiz atio n w ith the G3PDH probe w as use d as an RNA loading c ontro l for blots.
Results
Differentiation of the U937 line
The data (not show n) c onfirming that suitable diffe rentiation of the monocyte ce ll line tow ard mac rophage cells had be en achie ve d w ere as follow s: 
Determination of type of stimulus and most effective concentration on interleukin-6 secretion
In orde r to study the most suitable typ e of stimulus for induc ing the se cre tion of IL-6 and the most e ffec tive conc entratio n, U937 cells w e re used unde r both diffe re ntiate d and undiffe re ntiate d c onditio ns. Thre e classic stimuli w ere studie d at tw o diffe re nt conc entratio ns: lipopolysaccharide (LPS), phorbol myris tate acetate (PMA) and gamma-inte rfe ron (g -IFN). The me an value s of the re sults of the study carrie d out in quadrup lic ate are show n in Fig. 1 . Ove rall, the data obtaine d indic ate that the most pote nt stimulus of cytokine sec re tion w as PMA at a conce ntratio n of 10 -5 M. IL-6 sec re tion w as gre ate r by diffe re ntiate d U937 ce lls than by undiffe re ntiate d one s.
Effect of CsA on the synthesis of interleukin-6
The re sults of the effect of diffe re nt conc entratio ns of CsA on IL-6 se cre tion unde r both basal and stimulate d conditio ns are show n in Table 1 . These data show the me an value s obtaine d in four diffe re nt as says. As may be se en, both in undiffe re ntiate d and diffe re ntiate d U937 ce lls, at the highe st conce ntratio n use d (200 ng/ mL) CsA dec re ased stimulate d se cre tion of IL-6. Cs A can be said to decre ase the sec re tion of this cytokine more than 50%. The effect of CsA on basal IL-6 se cre tion w as much low e r. Using U937 ce lls diffe re ntiate d w ith 1.3% DMSO, the intrac ellular conte nt of IL-6 w as me as ure d afte r stimulatio n w ith phorbol myristate in tw o diffe re nt assays. At 200 ng/mL, CsA dec re as ed the intrac ellular conte nt of IL-6 from 151,0 ± 97,2 to 100,0 ± 61,3 pg/ 10 6 cells. So, CsA can be said to decre as e the production of cytokine s sinc e both the intra-and ex trac e llular c onte nts w ere affe c te d.
Cy c lo spo rin a n d m a c roph a g e IL-6 sy n th e sis
Effect of CsA on cell viability and cell proliferation capacity
The firs t and simple st possibility conside re d w as that CsA w ould affe ct ce ll viability and/or p rolife ration and he nce that the dec re ase in c ytokine produc tion w ould be due to a dec re as e in these c apacitie s. According ly, a duplicate study w as pe rforme d in w hich the prolife ratio n capac ity and c ell viability of a U937 line subjecte d to the same stimuli as those use d in the study w ere evaluate d. Table 2 show s the re sults of this study.
As seen, CsA did not affe ct either viability or prolife ratio n capac ity, either in undiffe re ntiate d U937 ce lls or in ce lls diffe re ntiate d w ith DMSO. There fore the re sults on c ytokine se cre tion canno t be inte rpre te d in the se te rms.
In this study, the e ffec ts of se veral stimulato ry substanc es w ere also assessed. Both PMA and LPS, but not gamma-inte rfe ron, w ere seen to decre as e ce ll viability.
Effect of cycloheximide on CsA inhibition of IL-6 production To study the mechanism by w hich CsA dec re as es IL-6 production, thre e w orking hypothe ses w ere addre ssed: that CsA affe cts the synthe sis of an early prote in, re spons ible for the de cre ase d le vels of the cytokine ; that it ex erts its ac tion at trans criptional level, and that its e ffec t is mediate d at post-trans criptional le ve l.
The first mechanism proposed w as evaluate d by tre atment w ith c yclohex imide (an inhibitor of prote in synthe sis) of diffe re ntiate d U937 c ells during the first 3 hours of culture . Prio r to this study it w as asce rtaine d that cyclohex imide does not affe ct ce ll viability (data not show n).
The e ffec t of cyclohex imide on the sec re tion of IL-6 is detaile d in Fig. 2 . As may be see n, although ove rall this drug de cre ased both bas al and stimulate d cytokine se cre tion in diffe re ntiate d ce lls, w hich w as ex pe cte d, the inhibitory e ffec t of CsA persis te d in all case s. It is the re fore unlike ly that the me chanism of action of CsA w ould de pend on inhibition of the synthe sis of an e arly p rote in. Figure 3 show s the re sults of one of the assays . As may be seen, CsA did not affe c t the le ve ls of IL-6 mRNA unde r eithe r basal or stimulate d conditions . 
Discussion
Differentiation of the U937 cell line
Study of the me chanism of ac tion of CsA on inflammatory c ytokine produc tion by human mac rophages could have bee n carrie d out in tissue mac rophages obtaine d ex vivo . How eve r, the limite d numbe r of ce lls availab le for the diffe re nt ex pe riments, together w ith the diffic ulty invo lve d in obtaining healthy control ce lls, w ithin-group variab ility and, above all, the influe nce of the ac tion of the drug on othe r cells -espe cially lymphocyte s -counse lle d agains t this. There fore , to study the mechanis m of action of CsA on cytokine p roduc tion in mac rophages and to have available a suffic ie nt number of c ells, the possibility of using a monocyte c ell line -name ly, U937 c ells -w as implemente d. This had the additio nal advantag e of enabling study of a complete ly pure populatio n; that is, complete ly ex cluding the pre senc e of lymphocyte s, w hich might alte r the re sults obtaine d. The lite rature contains re fere nce s to use of the U937 ce ll line in the e valuatio n of diffe re nt macrophage functions. 14 This human c ell line grow s c ontinuou sly in suspe nsion and w as initially obtaine d from a pleural effusion in a patie nt w ith histiocytic lymphoma. 15 Its phenotype c orre sponds to immature monocyte cells arre ste d in a diffe re ntiatio n state close to the mye lomonocytic ste m ce ll. 15 It should be re calle d that macrophage s are highly diffe re ntiate d c ells and therefore have low prolife ratio n c apacity w hile c ell line s show a strong duplication rate . Thus, the first ste p in this part of the w ork w as to diffe re ntiate the human U937 monoc yte c ell line .
In the pre senc e of se ve ral substanc e s U937 cells unde rgo a process of diffe re ntiatio n and the re fore acquire morphological and func tional charac te ristic s similar to those of mac rophages. 16 Sinc e one of the inte re sts in the pre sent w ork w as to study the e ffec t of PMA on cytokine se cre tion, DMSO w as chosen as a Cy c lo spo rin a n d m a c roph a g e IL-6 diffe re ntiating agent be cause it displays diffe re ntiating capacity on the U937 c ell line . 17 Diffe re ntiation w as e valuate d by kine tic , morphological, c ytochemic al and mole cular te chniques. The re sults obtaine d, w hich w ere similar to those re porte d by other authors, 15, 17 allow ed us to conclude that the protoc ol used is inde ed able to diffe re ntiate this cell line .
Choice of cellular stimulus DMSO-diffe re ntiate d U937 c ells re tain their capacity to be stimulate d late r on w ith diffe re nt agents, 17 among them PMA. 18 It should be note d here that diffe re ntiation and activatio n are not inc ompatible conc epts and that it is in fac t possible to e mploy se veral substanc es 16 to ac tivate ce lls diffe re ntiate d w ith other age nts. Here , w e e valuate d the effec t of thre e know n macrophage stimulating agents and observe d that for this purpose the most suitable agent w as PMA at a conce ntratio n of 10 -5 M. Although ac cording to the lite rature low e r conc entratio ns of this substanc e are usually used, 15, 17 in each ex pe rime ntal syste m it is ne cessary to obtain e vide nce of the most e ffec tive conc entratio n in the induc tion of a give n effe ct. There fore in the pre se nt study the afore mentio ne d conce ntration w as use d. Although at this c onc entratio n PMA dire ctly decre ase s c ellular viability, from a quantitativ e point of vie w the inc re as e that it induc es in cytokine se cretion canno t be attrib ute d to the eliminatio n of cytokine s by dead ce lls.
Production of interleukin-6 by U937 cells
Onc e the re quire d ex perime ntal conditions had be en establis hed, IL-6 sec re tion by U937 ce lls w as studie d. The se cre tion of IL-6 w as stronger in diffe re ntiate d than in undiffe re ntiate d c ells. Rec ently it has be en re porte d that the CD4 19 and CD23 20 surfac e molecules pre sent in diffe re ntiate d MPS c ells are invo lve d in the se cre tion of IL-6 by U937 cells. Although none of the m use d a protoc ol ide ntic al to the one use d he re , diffe re nt studie s have documente d the production of diffe re nt inflammatory c ytokine s by these c ells using bioassays, 21 immunoassays [22] [23] [24] [25] or molec ular biology te chnique s. 21, 24 Has s e t a l. 22 did not de te c t IL-6 secre tion, possibly due to the stimulatio n c onditions, and the value s described by Jiang e t a l. 23 for IL-6 are low er than our ow n, although the y use d diffe re nt protoc ols.
Effect of CsA on interleukin-6 production
Both in undiffe re ntiate d and diffe re ntiate d U937 ce lls, at the highest conce ntration use d use d (200 ng/mL) CsA dec re ased stimulate d se cre tion of IL-6, more than 50%, a value similar to that re porte d by Moutbarrik e t a l. 26 In human monocyte s at therapeutic c onc entrations in v ivo . Additionally, CsA decre as ed the intrac e llular conc entratio n of IL-6. According ly, in the diffe re ntiate d U937 ce ll line CsA can be said to dec re ase the produc tion of inflammatory c ytokine s. The effect of CsA on the U937 ce ll line is not w ell documente d. In a re vie w of the lite rature no re fere nc es to the se phenome na w ere found.
Mechanism of action of CsA on the production of interleukin-6
From the theore tic al point of vie w, the effe ct of CsA on the produc tion of inte rle ukin-6 could be due to a decre as e in cell viability and prolife ration and henc e to a de cre ase in the number of producing c ells, to the alte ration of an e arly prote in that w ould re gulate the gene ex pre ssion of cytokine s, to a dire ct action on gene trans cription, or to a modific atio n of posttrans c riptional events. The data obtaine d here allow us to ex clude a dire ct effect of CsA on ce ll prolife ration and viability. We c an also ex clude its ac tion at e arly le ve l sinc e inc ubatio n w ith c yclohex imide during the first hours of inc ubation did not affe c t the inhibitory effe ct of CsA. The ex pe cte d decre ase in IL-6 produc tion by U937 c ells due to the ac tion of cyclohex imide is c onsiste nt w ith the obse rvatio ns of othe r authors 27 w ho have re porte d that this drug inhibits stimulatio n of IL-1b synthe sis in the U937 cell line .
Finally, this immunomodulator does not alte r IL-6 mRNA ex pre ssion, allow ing us to conclude that the effect of Cs A on IL-6 produc tion occurs at posttrans c riptional level. Re sults similar to those obtaine d by us have bee n publishe d by Kato e t a l. 28 w ho observe d that CsA sc arc e ly affe c ts the ex pre ssion of the IL-6 gene in human periphe ral blood monocyte s. Like w ise , in a murine mast ce ll line Nair e t a l. 29 re porte d that CsA doe s not alte r IL-6 mRNA ex pre ssion although it does affe ct IL-3 mRNA. It w ould thus appear that in the human MPS CsA has little effect on the trans c ription of monokine gene s sinc e the mRNA levels of IL-1, 30 TNF 30 and IL-8 31 are not affe cte d by CsA e ithe r.
The ex act mechanism by w hich CsA ex erts its effect on cells of the MPS is not know n although it has bee n suggeste d that its e ffec t could be re late d to an inhibition of p rote in se cre tion/synthesis . 32, 33 If, as comme nte d earlie r, it is true that CsA inhibits the se cre tion of inflammator y cytokine s and does not affe c t the trans cription of the ir gene s, its action w ould appear to oc cur at post-trans c riptional le vel.
In vie w of the de cre ase in immunogenic prote in, CsA may ac t at some ste p betw ee n mRNA and synthe sis of the prote in. Although this as pec t w as not studie d ex plic itly in the pre se nt w ork, the ide a that CsA might act on intrac e llular membrane s invo lve d in prote in synthe sis c ould be ente rtaine d. At least thre e theore tic al possibilitie s could be advanc ed to account for this. Firs t, one could be de aling w ith a non-spec ific inte rac tion, ow ing to the lipophilic nature of this immunomodulator. In this sense , it has be en demonstrate d that othe r lipophilic substanc e s or lipid emulsions are able to inhibit c ytokine produc tion by macrophage s through this mechanism. 34 Sec ond, although there is no conse nsus about the possibility, 35, 36 CsA might inhibit prote in kinas e C activity in macrophage s. Thus, it has re ce ntly been observe d that inhibition of this e nzyme dec re ases TNF-a produc tion in LPS-stimulate d macrophage s. 37 Finally, another possibility w ould be that one w ould be dealing w ith a spe cific ac tion derive d from the inte rac tion of CsA w ith c ytokine s associate d w ith intrac ellular membrane s. 38 Furthe r studie s are e vide ntly re quire d to clarify all the se aspec ts.
It should be note d that some authors have situate d the site of action of CsA on monokine se cre tion at the level of re le as e sinc e the y obse rve d a dec re as e in the se cre tion of TNF-a w ith normal ex pre ssion of the ge ne and normal intrac ellular cytokine synthe sis. 13 Howe ve r, the se studie s w ere c arrie d out in mouse MPS cells w hile those use d here w e re from a human sourc e.
Acc ording ly, it may be c onc luded that at therapeutic and non-tox ic conc entratio ns in v ivo , CsA decre as es the produc tion of inte rleukin-6 by human macrophage s at post-trans criptional le ve l.
